TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

Alan S Gamis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.